Trial Profile
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs JCAR 018 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2024 Status changed from suspended to active, no longer recruiting.
- 04 Nov 2023 Status changed from recruiting to suspended.
- 15 May 2021 Planned number of patients changed from 126 to 208.